Onyx Kicks Off Pipeline Expansion By Buying TS Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Preclinical oncologic in-licensed from BTG offers opportunity in ovarian, lung, breast and colorectal cancers, biotech says.